Filter Articles
September 6, 2018
Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP
David Saperstein, MDCo-Director GBS/CIDP Center of ExcellencePhoenix Neurological AssociatesPhoenix, AZ Intravenous immunoglobulin (IVIg) is one…
March 19, 2018
FDA approves CSL Behring treatment for CIDP
The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating…
February 26, 2018
Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barré syndrome
February 16, 2018 Hansa Medical today announced that the U.S. Food and Drug Administration (FDA)…
June 21, 2013
To All Those With Chronic Inflammatory Demyelinating Polyneuropathy
Recently, one of the physicians on the GBS/CIDP Foundation Medical Advisory Board saw a man…